

Supplementary Information

Treatment Arms	Assigned Intervention
Arm 1: Active Comparator	
Basiliximab 20 mg day 0 and 4 + MMF 2x1 g i.v./d from day 0 (switched to oral administration after 1 week) + low level cyclosporine [start at day 5 after OLT, trough-level 100-150 ng/mL (CsA)] + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx.	Delayed, low-dose CNI-based immunosuppression
Arm 2: Active Comparator	
Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + low-level cyclosporine (start within 30 days after LTx; trough level 100-150ng/mL (CsA).	Bottom-up, CNI-based immunosuppression
Arm 3: Experimental	
Basiliximab 20 mg Tag 0 and 4 + MMF 2x1 g i.v./d from day 0 (switched to oral administration after 1 week) + low-level steroids 1 mg/kg KG/d from day 0, elimination by month 6 after LTx + everolimus (start within 30 days after LTx; trough-level 6-10 ng/mL).	Bottom-up, everolimus-based immunosuppression

Supplement: Overview of immunosuppressive therapy in the “CNI-free, ‘Bottom-up’ Immunosuppression in Patients Undergoing Liver Transplantation’ (BUiLT) Study.